Skip to main content
Midas Edge

Theriva Biologics, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

TOVX$0.15-7.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholder’s Equity

(In thousands, except share and par value amounts)

​​​​​​​​​​​​​​​​​​​​
​ · ​ · Common Stock $0.001 Par Value · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · Other · ​ · ​ · ​ · Total
​ · ​ · ​ · ​ · ​ · ​ · ​ · Paid-in · ​ · Accumulated · ​ · Comprehensive · ​ · ​ · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Deficit · ​ ​ ​ · Loss · ​ ​ ​ · Treasury Stock · ​ ​ ​ · Equity
​​​​​​​​​​​​​​​​​​​​
Balance at December 31, 2023715,028​$1$346,536​$(309,318)​$32​(288)​$36,963
​​​​​​​​​​​​​​​​​​​​
Stock-based compensation—​—​671​—​—​—​671
Stock issued under “at-the-market” offering569,282​1​3,602​—​—​—​3,603
Issuance of Common Stock and Warrants, net of issuance costs​918,600​​1​​1,959​​—​​—​—​​1,960
Series C Preferred Stock conversion to Common​72,132​​—​​2,005​​—​​—​—​​2,005
Series D Preferred Stock conversion to Common​26,230​​—​​728​​—​​—​—​​728
Conversion of Pre-Funded Warrants to Common509,987​—​​—​​—​—​—​​—
Foreign currency exchange loss—​—​—​—​(1,210)​—​(1,210)
Net loss​—​​—​​—​​(25,653)​​—​—​​(25,653)
​​​​​​​​​​​​​​​​​​​​
Balance at December 31, 20242,811,259​$3$355,501​$(334,971)​$(1,178)​(288)​$19,067
​​​​​​​​​​​​​​​​​​​​
​ · ​ · Common Stock $0.001 Par Value · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Other · ​ · ​ · ​ · Total
​ · ​ · ​ · ​ · ​ · ​ · ​ · Paid-in · ​ · Accumulated · ​ · Comprehensive · ​ · ​ · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Deficit · ​ ​ ​ · Loss · ​ ​ ​ · Treasury Stock · ​ ​ ​ · Equity
​​​​​​​​​​​​​​​​​​​​
Balance at December 31, 20242,811,259​$3​$355,501​$(334,971)​$(1,178)(288)​$19,067
​​​​​​​​​​​​​​​​​​​​
Stock-based compensation—​—​654​—​——​654
Stock issued under “at-the-market” offering17,998,117​18​6,815​—​——​6,833
Issuance of Common Stock and Warrants, net of issuance costs​1,990,900​​2​​6,688​​—​​—​—​​6,690
Warrant Inducement, net of issuance costs​8,092,280​​8​​3,933​​—​​—​—​​3,941
Conversion of Pre-Funded Warrants to Common4,824,603​3​1​—​——​4
Foreign currency exchange loss—​—​—​—​1,933—​1,933
Net loss—​—​—​(23,739)​——​(23,739)
​​​​​​​​​​​​​​​​​​​​
Balance at December 31, 202535,717,159​$34​$373,592​$(358,710)​$755(288)​$15,383
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.